Skip to main content
Year archive

IMUGENE LIMITED — 2025 filings

All 103 regulatory filings released by IMUGENE LIMITED (IMU) in 2025, sourced directly from the official regulator.

103 Filings
2025 Period
2025 filings (103)
Filing Released Lang
Cleansing Notice 2 pages 178.5KB
Share Issue/Capital Change
2025-12-22 English
Notification regarding unquoted securities - IMU 10 pages 27.6KB
Share Issue/Capital Change
2025-12-21 English
Notification of cessation of securities - IMU 5 pages 17.3KB
Share Issue/Capital Change
2025-12-21 English
Notification regarding unquoted securities - IMU 9 pages 25.8KB
Share Issue/Capital Change
2025-12-21 English
Application for quotation of securities - IMU 8 pages 21.1KB
Share Issue/Capital Change
2025-12-21 English
Proposed issue of securities - IMU 6 pages 23.1KB
Capital/Financing Update
2025-12-18 English
Change of Director's Interest Notice x5 10 pages 29.6KB
Director's Dealing
2025-12-18 English
Application for quotation of securities - IMU 10 pages 28.2KB
Share Issue/Capital Change
2025-12-18 English
Amendment of Convertible Notes 9 pages 338.1KB
Capital/Financing Update
2025-12-17 English
Letter to Shareholders 8 pages 381.0KB
Management Reports
2025-12-16 English
FDA Supports Strategy Toward Registration for Azer-cel 6 pages 218.1KB
Capital/Financing Update
2025-12-07 English
Investor Webinar FDA Meeting 2 pages 155.0KB
Investor Presentation
2025-12-07 English
Overall Response Rate increases to 82% in azer-cel trial 5 pages 330.5KB
Regulatory Filings
2025-11-30 English
Strategic Collaboration with JW Therapeutics 3 pages 214.2KB
Capital/Financing Update
2025-11-26 English
Investor Webinar JW Therapeutics Collaboration 2 pages 155.9KB
Investor Presentation
2025-11-26 English
Annual General Meeting Presentation 16 pages 2.0MB
AGM Information
2025-11-12 English
Results of 2025 Annual General Meeting 4 pages 145.9KB
Declaration of Voting Results & Voting Rights Announcements
2025-11-12 English
Imugene selected for Oral Presentation at ASH Annual Meeting 3 pages 160.2KB
Regulatory Filings
2025-11-03 English
Investor webinar on CAR T naive lymphomas & ASH presentation 2 pages 156.7KB
Investor Presentation
2025-11-03 English
Becoming a substantial holder 3 pages 822.6KB
Major Shareholding Notification
2025-11-03 English
azer-cel Development Milestone Reached 3 pages 165.0KB
Capital/Financing Update
2025-11-02 English
Application for quotation of securities - IMU 8 pages 22.1KB
Share Issue/Capital Change
2025-11-02 English
Cleansing Notice 2 pages 212.7KB
Capital/Financing Update
2025-11-02 English
Quarterly Activities/Appendix 4C Cash Flow Report 13 pages 547.3KB
Interim / Quarterly Report
2025-10-30 English
Early azer-cel efficacy in CAR T naive lymphomas 5 pages 269.0KB
Regulatory Filings
2025-10-28 English
PD1-Vaxx to Feature at ESMO 2025 3 pages 173.4KB
Regulatory Filings
2025-10-19 English
Notice of Annual General Meeting/Proxy Form 55 pages 1.8MB
AGM Information
2025-10-12 English
Application for quotation of securities - IMU 8 pages 21.1KB
Share Issue/Capital Change
2025-10-12 English
Overall Response Rate increases to 81% in azer-cel trial 5 pages 314.5KB
Capital/Financing Update
2025-09-17 English
Application for quotation of securities - IMU 8 pages 21.4KB
Capital/Financing Update
2025-09-01 English
Application for quotation of securities - IMU 8 pages 21.1KB
Share Issue/Capital Change
2025-08-31 English
Final Share Purchase Plan Allotment 3 pages 164.2KB
Capital/Financing Update
2025-08-27 English
Application for quotation of securities - IMU 9 pages 24.9KB
Capital/Financing Update
2025-08-26 English
Listed Options Top Holders Grouped & Holdings Range Report 3 pages 89.9KB
Major Shareholding Notification
2025-08-26 English
Appendix 4E and Annual Report 114 pages 5.6MB
Annual Report
2025-08-25 English
Corporate Governance Statement 2025 and Appendix 4G 24 pages 681.9KB
Governance Information
2025-08-25 English
EGM Presentation 6 pages 465.7KB
Investor Presentation
2025-08-19 English
Results of Meeting 3 pages 176.7KB
Declaration of Voting Results & Voting Rights Announcements
2025-08-19 English
Ceasing to be a substantial holder 3 pages 351.3KB
Major Shareholding Notification
2025-08-17 English
Update - Proposed issue of securities - IMU 9 pages 31.5KB
Capital/Financing Update
2025-08-11 English
Share Purchase Plan Closing Date Extended 3 pages 165.3KB
Capital/Financing Update
2025-08-10 English
79% Overall Response Rate With Two Further Partial Responses 5 pages 303.3KB
Regulatory Filings
2025-08-03 English
Quarterly Activities/Appendix 4C Cash Flow Report 15 pages 423.9KB
Interim / Quarterly Report
2025-07-30 English
Application for quotation of securities - IMU 8 pages 22.0KB
Regulatory Filings
2025-07-23 English
Cleansing Notice 2 pages 234.5KB
Capital/Financing Update
2025-07-23 English
Application for quotation of securities - IMU 10 pages 28.2KB
Share Issue/Capital Change
2025-07-22 English
Change of Director's Interest Notice x2 5 pages 282.1KB
Director's Dealing
2025-07-22 English
Notice of Extraordinary General Meeting/Proxy Form 21 pages 376.0KB
Proxy Solicitation & Information Statement
2025-07-20 English
Change of Director's Interest Notice x 3 6 pages 2.2MB
Regulatory Filings
2025-07-17 English
Imugene Completes $22.5M Placement and c.$15M SPP 12 pages 358.8KB
Capital/Financing Update
2025-07-15 English
Proposed issue of securities - IMU 7 pages 24.5KB
Capital/Financing Update
2025-07-15 English
Proposed issue of securities - IMU 9 pages 29.9KB
Capital/Financing Update
2025-07-15 English
Imugene Capital Raising Presentation 37 pages 4.1MB
Capital/Financing Update
2025-07-15 English
Prospectus 51 pages 792.5KB
Capital/Financing Update
2025-07-15 English
Azer-cel new data Webinar 2 pages 150.0KB
Investor Presentation
2025-07-15 English
Application for quotation of securities - IMU 8 pages 21.7KB
Share Issue/Capital Change
2025-07-15 English
Two Additional Complete Responses in azer-cel Ph1b trial 6 pages 332.4KB
Capital/Financing Update
2025-07-13 English
Trading Halt 2 pages 193.8KB
Capital/Financing Update
2025-07-13 English
Imugene Receives $5.8m R&D Tax Refund 2 pages 153.1KB
Capital/Financing Update
2025-07-03 English
1st Patient Dosed in Australia PD1-Vaxx neo-POLEM PhII Trial 3 pages 182.4KB
Capital/Financing Update
2025-06-26 English
EGM Presentation 3 pages 511.7KB
AGM Information
2025-06-25 English
Results of Meeting 3 pages 169.9KB
Declaration of Voting Results & Voting Rights Announcements
2025-06-25 English
US patent allowance for onCARlytics 3 pages 184.0KB
Regulatory Filings
2025-06-17 English
Notification of cessation of securities - IMU 5 pages 16.9KB
Regulatory Filings
2025-06-05 English
1st Australian site activated PD1-Vaxx Neo-POLEM Ph II trial 3 pages 181.5KB
Regulatory Filings
2025-06-01 English
Dr John Byon appointed Chief Medical Officer 3 pages 188.6KB
Board/Management Information
2025-05-29 English
Consolidation/Split - IMU 10 pages 33.3KB
Share Issue/Capital Change
2025-05-28 English
Letter to Imugene Shareholders 3 pages 161.5KB
Capital/Financing Update
2025-05-27 English
Notice of Extraordinary General Meeting/Proxy Form 15 pages 282.8KB
AGM Information
2025-05-26 English
Addendum to Notice of Extraordinary General Meeting 3 pages 186.2KB
Proxy Solicitation & Information Statement
2025-05-26 English
Notification regarding unquoted securities - IMU 9 pages 24.6KB
Share Issue/Capital Change
2025-05-22 English
Notification of cessation of securities - IMU 6 pages 20.1KB
Share Issue/Capital Change
2025-05-20 English
Proposed Consolidation of Capital 3 pages 158.1KB
Share Issue/Capital Change
2025-05-15 English
Letter to Shareholders 7 pages 208.5KB
Management Reports
2025-04-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 13 pages 746.0KB
Interim / Quarterly Report
2025-04-29 English
Application for quotation of securities - IMU 8 pages 21.1KB
Share Issue/Capital Change
2025-04-13 English
Notification regarding unquoted securities - IMU 8 pages 21.1KB
Share Issue/Capital Change
2025-04-10 English
Notification of cessation of securities - IMU 6 pages 18.7KB
Regulatory Filings
2025-04-10 English
Investor Update & FAQ Webinar 2 pages 156.4KB
Regulatory Filings
2025-04-09 English
1st dose level cleared IV combination arm onCARlytics trial 3 pages 187.5KB
Regulatory Filings
2025-04-02 English
Azer-cel Granted FDA Fast Track Designation in Blood Cancer 3 pages 181.4KB
Regulatory Filings
2025-03-18 English
Application for quotation of securities - IMU 8 pages 21.5KB
Share Issue/Capital Change
2025-03-12 English
Darren Keamy Appointed CFO and Company Secretary 3 pages 194.5KB
Board/Management Information
2025-03-03 English
Half Yearly Report and Accounts 36 pages 1.3MB
Interim / Quarterly Report
2025-02-27 English
Imugene Granted India Patent for Oncolytic Virotherapy CF33 3 pages 160.9KB
Regulatory Filings
2025-02-26 English
Imugene OnCARlytics Patent Allowance in China 2 pages 151.8KB
Regulatory Filings
2025-02-25 English
Application for quotation of securities - IMU 8 pages 21.7KB
Share Issue/Capital Change
2025-02-20 English
Notification regarding unquoted securities - IMU 9 pages 25.8KB
Share Issue/Capital Change
2025-02-20 English
Change of Directors Interest Notice x 5 10 pages 26.6KB
Director's Dealing
2025-02-20 English
Azer-cel demonstrates two additional Complete Responses 5 pages 308.3KB
Capital/Financing Update
2025-02-13 English
Quarterly Activities/Appendix 4C Cash Flow Report 13 pages 527.6KB
Interim / Quarterly Report
2025-01-30 English
Imugene Receives A$20 million for Convertible Notes Issuance 2 pages 153.5KB
Capital/Financing Update
2025-01-28 English
Application for quotation of securities - IMU 8 pages 21.1KB
Regulatory Filings
2025-01-28 English
Notification of cessation of securities - IMU 5 pages 16.9KB
Regulatory Filings
2025-01-28 English
Notification regarding unquoted securities - IMU 10 pages 28.1KB
Share Issue/Capital Change
2025-01-27 English
Notification regarding unquoted securities - IMU 9 pages 25.1KB
Share Issue/Capital Change
2025-01-23 English
Cleansing Notice 15 pages 647.5KB
Capital/Financing Update
2025-01-23 English
Release of Shares from Voluntary Escrow 2 pages 156.6KB
Share Issue/Capital Change
2025-01-23 English
Imugene EGM Presentation 10 pages 1.1MB
Investor Presentation
2025-01-21 English
Results of Meeting 3 pages 167.1KB
Declaration of Voting Results & Voting Rights Announcements
2025-01-21 English
Imugene Receives $11.7m R&D Tax Refund 2 pages 148.9KB
Regulatory Filings
2025-01-09 English
Application for quotation of securities - IMU 10 pages 28.0KB
Share Issue/Capital Change
2025-01-09 English
First Australian Patient Dosed in Phase 1b azer-cel Trial 3 pages 180.5KB
Regulatory Filings
2025-01-02 English